Ramón Y. B.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1 Evaluation of BL-B01D1 Safety, Tolerability, and Efficacy in Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors
- Evaluation of Tuvusertib (M1774) Combined with DNA Damage Response or Immune Checkpoint Inhibitors in Metastatic or Locally Advanced Unresectable Solid Tumors
- Phase I Study of OKI-219 Monotherapy and in Combination with Endocrine or HER2-Targeted Therapy in Advanced Solid Tumors and Breast Cancer
Data & Insights
Has run more than one trial at 80 of 175 partner sites.
Specializations
Breast Cancer and Hormone Receptor-Driven Disease
Ramon Yarza is active in trials centered on advanced breast cancer, with particular attention to ER-positive, HER2-negative, HER2-positive, and triple-negative breast cancer. His research landscape includes metastatic breast cancer, early breast cancer, and biomarker-defined subgroups such as ESR1-mutated and PIK3CA-mutant disease.
- Endocrine therapy and selective estrogen receptor targeting
- HER2-directed therapy in early and advanced settings
- Biomarker-selected metastatic breast cancer
His work also extends to neoadjuvant and adjuvant breast cancer strategies, reflecting a strong therapeutic focus on disease control across the breast cancer continuum.
Thoracic Oncology and Lung Cancer
His clinical trial activity includes a broad commitment to non-small cell lung cancer, including EGFR exon 20 insertion disease, ALK-rearranged tumors, ROS1-positive malignancies, and metastatic squamous and non-squamous NSCLC. He is also involved in studies addressing small cell lung cancer and other advanced thoracic malignancies.
- Targeted therapy for molecularly defined NSCLC
- Immunotherapy combinations in advanced lung cancer
- Resistant and metastatic thoracic tumors
This area of interest also covers head and neck squamous cell carcinoma and esophageal cancer, linking thoracic and upper aerodigestive tract oncology.
Gastrointestinal and Hepatobiliary Cancers
Ramon Yarza participates in research involving colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma, and hepatocellular carcinoma. His trial portfolio also includes gastrointestinal stromal tumors and other advanced solid tumors of digestive origin.
- Metastatic colorectal cancer
- Advanced gastric and gastroesophageal junction cancer
- Pancreatic and biliary tract malignancies
His therapeutic interests include precision oncology approaches for molecularly selected gastrointestinal tumors and treatment-resistant disease.
Genitourinary and Gynecologic Oncology
His research landscape includes prostate cancer, metastatic castration-resistant prostate cancer, urothelial carcinoma, bladder cancer, renal cell carcinoma, and a wide spectrum of ovarian, endometrial, cervical, and fallopian tube cancers. He is also involved in studies of upper tract urothelial carcinoma and muscle-invasive bladder cancer.
- Prostate cancer and androgen receptor-directed treatment
- Urothelial and bladder cancer
- Ovarian and endometrial malignancies
This portfolio reflects sustained interest in both advanced disease and biomarker-guided therapeutic development across genitourinary and gynecologic cancers.
Hematologic Malignancies and Selected Solid Tumor Innovation
He is engaged in trials across multiple myeloma, myelodysplastic syndromes, acute myeloid leukemia, and diverse B-cell lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. His solid tumor portfolio also includes melanoma, glioblastoma, and molecularly selected advanced solid tumors.
- Plasma cell and myeloid disorders
- Lymphoid malignancies
- Mutation-driven solid tumors
His involvement spans novel immunotherapy, targeted therapy, and antibody-based approaches in advanced cancer settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.